公开(公告)号：EP2332958A1

公开(公告)日：2011-06-15

申请号：EP10075458.9

申请日：1997-02-05

申请人： Cornell Research Foundation, Inc. ,  REGENTS OF THE UNIVERSITY OF MINNESOTA ,  Louisiana State University

发明人： Barany, Francis ,  Barany, George ,  Hammer, Robert P. ,  Kempe, Maria ,  Blok, Herman ,  Zirvi, Monib

IPC分类号： C07H21/04 ,  C07H21/00 ,  C12Q1/68 ,  C12P19/34

CPC分类号： B01J19/0046 ,  B01J2219/00432 ,  B01J2219/00527 ,  B01J2219/00529 ,  B01J2219/00536 ,  B01J2219/00585 ,  B01J2219/0059 ,  B01J2219/00596 ,  B01J2219/00605 ,  B01J2219/00608 ,  B01J2219/0061 ,  B01J2219/00612 ,  B01J2219/00621 ,  B01J2219/00626 ,  B01J2219/00637 ,  B01J2219/00659 ,  B01J2219/00711 ,  B01J2219/00722 ,  B01J2219/00729 ,  B82Y30/00 ,  C07B2200/11 ,  C12Q1/6837 ,  C12Q1/689 ,  C40B20/02 ,  C40B50/14 ,  Y02A50/58 ,  C12Q2565/513 ,  C12Q2561/125

摘要： The present invention describes a method for identifying one or more of a plurality of sequences differing by one or more single base changes, insertions, deletions, or translocations in a plurality of target nucleotide sequences. The method includes a ligation phase, a capture phase, and a detection phase. The ligation phase utilizes a ligation detection reaction between one oligonucleotide probe, which has a target sequence-specific portion and an addressable array-specific portion, and a second oligonucleotide probe, having a target sequence-specific portion and a detectable label. After the ligation phase, the capture phase is carried out by hybridizing the ligated oligonucleotide probes to a solid support with an array of immobilized capture oligonucleotides at least some of which are complementary to the addressable array-specific portion. Following completion of the capture phase, a detection phase is carried out to detect the labels of ligated oligonucleotide probes hybridized to the solid support. The ligation phase can be preceded by an amplification process. The present invention also relates to a kit for practicing this method, a method of forming arrays on solid supports, and the supports themselves.

摘要翻译： 本发明描述了用于识别一个或多个由一个或多个单碱基变化，插入，缺失，易位或在靶核苷酸序列的多种不同序列的多个方法。 该方法包括：一个相连接，一个捕获阶段和检测阶段。 结扎相位利用一个寡核苷酸探针，其具有可寻址的阵列特异性部分的靶序列特异性部分和探针，和第二寡核苷酸之间的连接检测反应，具有目标序列特异性部分和可检测标记。 结扎阶段之后，捕获相位由连接的寡核苷酸探针与固定化在捕获寡核苷酸的阵列的至少一些是可寻址的阵列特异性部分互补杂交的固体支持体上进行。 以下捕获阶段完成后，检测相位进行检测杂交至在固体支持连接的寡核苷酸探针的标签。 结扎相可通过在扩增过程之前。 因此，本发明涉及一种试剂盒，用于实施该方法中，形成在固体载体上阵列的方法，以及支持他们自己。

公开(公告)号：EP2297175A2

公开(公告)日：2011-03-23

申请号：EP09759412.1

申请日：2009-06-04

申请人： Uniwersytet Warszawski ,  Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

发明人： KOWALSKA, Joanna ,  JEMIELITY, Jacek ,  DARZYNKIEWICZ, Edward ,  RHOADS, Robert, E. ,  LUKASZEWICZ, Maciej ,  ZUBEREK, Joanna

IPC分类号： C07H21/00 ,  C07H21/02

CPC分类号： C07H21/00 ,  C07H21/02 ,  C12N15/67 ,  C12P21/02

摘要： Dinucleotide cap analogs are disclosed, modified at different phosphate positions with a boranophosphate group or a phosphoroselenoate group. The analogs are useful as reagents in the preparation of capped mRNAs and have increased stability both
in vitro and
in vivo . They may be used as inhibitors of cap-dependent translation. Optionally, the boranophosphate or phosphoroselenoate group has a 2'-O or 3'-O-alkyl group, preferably a methyl group, producing analogs called BH
3 -ARCAs or Se-ARCAs. ARCAs may be modified with α-, β-, or γ-boranophosphate or phosphoroselenoate groups.

摘要翻译： 公开了二核苷酸帽类似物，其在不同的磷酸位置用硼烷磷酸酯基团或磷酸硒代酸酯基团进行修饰。 该类似物可用作制备加帽mRNA的试剂，并且在体外和体内都具有增加的稳定性。 它们可以用作帽依赖性翻译的抑制剂。 任选地，硼烷磷酸酯或磷酸硒化酯基团具有2'-O或3'-O-烷基，优选甲基，产生称为BH 3 -ARA或Se-ARCA的类似物。 可以用α-，β-或γ-硼烷磷酸酯或磷酸硒酸酯基团修饰ARCAs。

公开(公告)号：EP2219657A2

公开(公告)日：2010-08-25

申请号：EP08849380.4

申请日：2008-11-17

申请人： Biomedical Research Foundation of Northwest Louisiana ,  Louisiana State University ,  The UAB Research Foundation

发明人： KEVIL, Christopher ,  LEFER, David ,  PATEL, Rakesh

IPC分类号： A61K33/14 ,  A61K33/06 ,  A61P7/06

CPC分类号： A61K33/06 ,  A61K33/00 ,  A61K45/06

摘要： Methods of treating a subject who has chronic tissue ischemia are disclosed. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to result in blood vessel growth in the ischemic tissue. The subject can be diagnosed as having a medical condition that results in persistent or recurring restriction of blood supply to a tissue, for example, peripheral artery disease, diabetes, atherosclerotic cardiovascular disease or defective wound healing. The methods can include the step of identifying a suitable subject.

摘要翻译： 公开了治疗患有慢性组织缺血的受试者的方法。 所述方法可以包括向受试者施用包含无机亚硝酸盐或其药学上可接受的盐的药物组合物，其时间和量足以导致缺血组织中的血管生长。 该受试者可以被诊断为具有导致对组织的血液供应的持续或重复限制的医学病症，例如外周动脉疾病，糖尿病，动脉粥样硬化心血管疾病或有缺陷的伤口愈合。 所述方法可以包括鉴定合适的受试者的步骤。

公开(公告)号：EP2076189A2

公开(公告)日：2009-07-08

申请号：EP07811021.0

申请日：2007-07-31

申请人： Board of Supervisors, Louisiana State University and Agricultural College

发明人： LOPEZ, Mandi, J. ,  MONROE, W., Todd

IPC分类号： A61B17/58

CPC分类号： A61F2/0811 ,  A61F2002/0829 ,  A61F2002/0864 ,  A61F2002/0882

摘要： A soft tissue fixation device for use in ACL or CrCL reconstruction has a base member provided with a tissue passageway extending perpendicularly from its top surface through its bottom surface. An affixing member is attachable to the base member. Teeth may extend from the affixing member. Tissue glue or at least one perpendicularly extending spike is used to secure the base member to bone.

公开(公告)号：EP1928487A2

公开(公告)日：2008-06-11

申请号：EP06800865.5

申请日：2006-08-07

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： BUTLER, Andrew, A. ,  TREVASKIS, James, L.

IPC分类号： A61K38/17 ,  C07K14/705

CPC分类号： C07K14/47 ,  A61K38/1709 ,  A61K38/22 ,  A61K38/2264 ,  C07K14/4702 ,  C07K16/18 ,  G01N33/68

摘要： The expression of a mRNA encoding a putative 76 amino acid, secreted protein ('Swirl') was found to negatively correlate with fasting triglyceride and cholesterol levels. A recombinant adenovirus was used to increase the expression of Swirl mRNA in two mouse models of obesity, KK-Ay and Lepob/Lepob mice. Over-expression of Swirl by adenovirus injection significantly, and reproducibly, reduced fasting triglyceride and cholesterol levels in both models. In addition, transgenic mice strains were made that over express Swirl protein. The expression of a key gene involved in lipogenesis (fatty acid synthase) and FAS protein levels were reduced by SWIRl adenoviral treatment in Lepob/Lepob mice. Full-length SWIRl peptide, or peptide derivatives, homologues, analogues, or mimetics thereof, delivered by oral intake, injection, subcutaneous patch, or intranasal routes, could be used as therapeutic or diagnostic agents for hypercholesterolemia, hypertriglyceridemia, insulin resistance, obesity, diabetes, and/or energy imbalance.

公开(公告)号：EP1888102A2

公开(公告)日：2008-02-20

申请号：EP06784696.4

申请日：2006-06-09

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： GIMBLE, Jeffrey, M.

IPC分类号： A61K38/17

CPC分类号： A61K38/28 ,  A61K31/4015 ,  A61K31/44 ,  A61K31/616 ,  A61K33/00 ,  A61K38/31 ,  G01N33/5023 ,  G01N33/6893 ,  G01N2800/02 ,  G01N2800/042 ,  G01N2800/303

摘要： Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erba, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte-differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight gain or loss, respectively.

公开(公告)号：EP1648475B1

公开(公告)日：2007-09-12

申请号：EP04777982.2

申请日：2004-07-09

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE ,  UNIVERSITY OF ALABAMA RESEARCH FOUNDATION ,  LOMA LINDA UNIVERSITY ,  WAKE FOREST UNIVERSITY

发明人： GLADWIN, Mark, T. ,  SCHECHTER, Alan, N. ,  LEFER, David, J. ,  PATEL, Rakesh, P. ,  HUNTER, Christian J., National Inst. of Health ,  POWER, Gordon, G. ,  KIM-SHAPIRO, Daniel, B. ,  PLUTA, Ryszard National Institutes of Health NINDS ,  OLDFIELD, Edward, H. ,  CANNON III, Richard, O.

IPC分类号： A61K33/00 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12

CPC分类号： A61K33/00 ,  A61K45/06 ,  A61K2300/00

摘要： It has been surprisingly discovered that administration of nitrite to subjects causes a reduction in blood pressure and an increase in blood flow to tissues. The effect is particularly beneficial, for example, to tissues in regions of low oxygen tension. This discovery provides useful treatments to regulate a subject's blood pressure and blood flow, for example, by the administration of nitrite salts. Provided herein are methods of administering a pharmaceutically-acceptable nitrite salt to a subject, for treating, preventing or ameliorating a condition selected from: (a) ischemia-reperfusion injury (e.g., hepatic or cardiac or brain ischemia-reperfusion injury); (b) pulmonary hypertension (e.g., neonatal pulmonary hypertension); or (c) cerebral artery vasospasm.

公开(公告)号：EP0833636B1

公开(公告)日：2006-08-23

申请号：EP96922478.1

申请日：1996-06-05

申请人： PLIVA D.D. ,  THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： MEIER, Albert, H. ,  CINCOTTA, Anthony, H.

IPC分类号： A61K31/40 ,  A61K31/48 ,  A61P35/00

CPC分类号： A61K31/166 ,  A61K31/4045 ,  A61K31/405 ,  A61K31/454 ,  A61K31/48 ,  A61K38/2257 ,  A61K31/40 ,  A61K2300/00

摘要： This invention relates to a method for inhibiting the growth of neoplasms, in a mammal having a prolactin profile. This method involves comparing the prolactin profile of the afflicted mammal to a standard prolactin profile for healthy mammals of the same species and sex and adjusting the prolactin profile of the afflicted mammal to conform to or approach the standard prolactin profile for a mammal of the same species and sex of the afflicted mammal, thereby inhibiting the neoplastic growth.

公开(公告)号：EP1592789A2

公开(公告)日：2005-11-09

申请号：EP03800225.9

申请日：2003-12-24

申请人： Transgenrx, Inc. ,  THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： COOPER, Richard, K. ,  FIORETTI, William, C. ,  CADD, Gary G.

IPC分类号： C12N15/00 ,  C12N15/63 ,  C12P21/00 ,  A01K67/027

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/01 ,  A23L15/00 ,  A23V2002/00 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/62 ,  C07K16/00 ,  C07K16/02 ,  C07K16/1063 ,  C07K16/26 ,  C07K2317/23 ,  C07K2317/34 ,  C12N15/85 ,  C12N2800/90 ,  C12N2830/003 ,  C12N2830/008 ,  C12N2830/90 ,  C12N2840/20 ,  Y02A50/407 ,  Y02A50/469 ,  A23V2300/21

摘要： Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.

公开(公告)号：EP1432429A1

公开(公告)日：2004-06-30

申请号：EP02775733.5

申请日：2002-08-30

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： WOLTERING, Eugene, A. ,  HORNICK, Conrad, A. ,  MYERS, Amy, E.

IPC分类号： A61K35/78

CPC分类号： C08B37/006 ,  A23L2/02 ,  A23L33/105 ,  A61K36/746 ,  Y02A50/401

摘要： Noni juice and a protein-free, alcohol precipitate of Noni juice inhibited angiogenesis in in vitro human angiogenesis models. When growth medium contained Noni juice at least over the range from about 2.5% to about 33% (by volume), angiogenesis was blocked. Moreover, Noni juice and an ethanol precipitate were able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Noni juice was effective in inhibiting the growth of angiogenic vessels from breast cancer explants. It will also be effective in treating cancers and non-cancerous diseases whose response includes an increase in angiogenesis, e.g., retinopathy of prematurity, neovascular glaucoma, diabetic retinopathy, and psoriasis. The primary antiangiogenic component is believed to be a carbohydrate with a molecular weight less than about 6000 Daltons. In an initial experiment, oral administration of Noni juice appeared to adversely affect the antioangiogenic component(s) in the juice.